BioWorld

Dec. 17, 2002

MedImmune, Corixa Take Cases To FDA Advisory Committees

While The Street is leaning toward a favorable vote for MedImmune Inc.'s FluMist as an intranasal influenza vaccine, it's not so clear whether Seattle-based Corixa Inc. will get the nod for its cancer drug, Bexxar. (BioWord Today) Read More

CDP 870 Becomes Inhale's 4th PEG Product In Pivotal Trials

NIH Structural Biologists Dissect AIDS Virus Triple-Threat Infection, Quick Change, Immunity Evasion

AdipoGenix Lands Deal With J&J For Program In Obesity

Goodman Named To Replace Zoon As Director Of CBER

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...